|本期目录/Table of Contents|

[1]杨 露,成 玮,丁长花,等.谷氨酰胺降低2型糖尿病患者血糖的机制探讨[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):127-130，178.[doi:10.3969/j.issn.1672-271X.2015.02.005]
　YANG Lu,CHENG Wei,DING Chang-hua,et al.A study on the action and mechanism of glutamine in reducing postprandial glycemia in type 2 diabetes mellitus[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(02):127-130，178.[doi:10.3969/j.issn.1672-271X.2015.02.005]
点击复制

谷氨酰胺降低2型糖尿病患者血糖的机制探讨()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第17卷
期数:
2015年02期
页码:
127-130，178
栏目:
出版日期:
2015-04-22

文章信息/Info

Title:
A study on the action and mechanism of glutamine in reducing postprandial glycemia in type 2 diabetes mellitus
作者:
杨 露1; 成 玮1; 丁长花1; 宋敬云1; 林红梅1; 胡艳艳2; 陈晶波1; 黄 勤1
1.200433 上海，第二军医大学附属长海医院内分泌科；2.200072 上海，上海市第十人民医院内分泌科
Author(s):
YANG Lu1;  CHENG Wei1;  DING Chang-hua1;  SONG Jing-yun1;  LIN Hong-mei1;  HU Yan-yan2;  CHEN Jing-bo1;  HUANG Qin1.
1. Department of Endocrinology， Changhai Hospital， Second Military Medical University， Shanghai 200433， China； 2. Department of Endocrinology， Shanghai Tenth People’s Hospital， Shanghai 200072， China
关键词:
2型糖尿病; 谷氨酰胺; 胰高糖素样肽-1; 葡萄糖依赖性促胰岛素分泌多肽
Keywords:
type 2 diabetes mellitus;  glutamine;  glucagon-like peptide-1;  glucose-dependent insulinotropic peptide
分类号:
R587.1
DOI:
10.3969/j.issn.1672-271X.2015.02.005
文献标志码:
A
摘要:
目的 明确口服谷氨酰胺（glutamine，Glu）是否通过升高胰高糖素样肽-1（glucagon-like peptide-1，GLP-1）对早期2型糖尿病（type 2 diabetes mellitus，T2DM）患者餐后血糖和胰岛功能有改善作用。方法 选取9例血糖控制良好且病程小于3年的T2DM患者，首次试验患者晨起空腹仅给予低脂餐(作为对照组)，第二次试验用低脂餐前口服100 mg西格列汀，第三次试验用低脂餐前口服30 g Glu，每次试验间隔1～2周，观察进餐前后血糖、胰岛素、C肽、胰高糖素样肽-1（glucagon-like peptide-1，GLP-1）等水平及曲线下面积（area under curve，AUC）。结果 与对照组比较，Glu和西格列汀均可显著降低餐后血糖水平（均P＜0.05），且Glu的早期降低血糖作用更为明显（P＜0.01）；与对照组比较，Glu组GLP-1水平在进餐后呈增高趋势，葡萄糖依赖性促胰岛素分泌多肽(glucose-dependent insulinotropic peptide，GIP)水平在餐后60 min 到180 min间显著升高（P＜0.05）；与自身基线值（空腹）比，服用Glu后血游离脂肪酸（free fatty acids，FFA）水平在餐后60、120和180 min均显著降低（均P＜0.05）。结论 Glu可升高GLP-1水平，改善早期T2DM患者餐后血糖，疗效与西格列汀相当，但确切机制尚未阐明。
Abstract:
Objective To test whether glutamine (Glu) ameliorates postprandial glycemia and pancreatic islet function through elevation of glucagon-like peptide-1(GLP-1) in subjects with early-stage type 2 diabetes mellitus (T2DM). Methods We recruited 9 type 2 diabetics in good glycemic control and with duration less than 3 years. Subjects were given low-fat breakfast only on the first visit. 100 mg sitagliptin and 30g glutamine (Glu) were administered before the low-fat meal respectively on the second and the third visits. Visits were conducted 1-2 weeks apart. Blood glucose， insulin， C-peptide， GLP-1 of each patient before and after the meal were assayed. The measurement and area under curve (AUC) of each parameter were analyzed. Results Compared with control， Glu and sitagliptin both significantly reduced postprandial glycemic response (both P＜0.05) and it had a more obvious effect in reducing postprandial glycemia at an early stage (P＜0.01). Compared with control， Glu tended to increase postprandial GLP-1 levels and significantly increased glucose-dependent insulinotropic peptide (GIP) levels 60 to 180 minutes after the meal (P＜0.05). Compared with their own baseline values， subjects on glutamine tended to have higher postprandial levels of GLP-1 and significantly higher levels of GIP 60 to 180minutes after the meal (P＜0.05). Compared with its baseline values， Glu caused a more pronounced reduction in serum free fatty acid(FFA) levels at the 60， 120 and 180 minutes postprandially (all P＜0.05). Conclusion Glu could increase circulating GLP-1 levels and alleviate postprandial glycemia in patients with early-stage T2DM. The therapeutic effect of Glu is close to that of sitagliptin but the exact mechanism remains to be elucidated.

参考文献/References:

［1］Galera SC，Fechine FV，Teixeira MJ，et al.The safety of oral use of L-glutamine in middle-aged and elderly individuals［J］.Nutrition (Burbank，Los Angeles County，Calif.)，2010，26(4)：375-381.
［2］Reimann F，Williams L，Da Silva Xavier G，et al.Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells［J］.Diabetologia，2004，47(9)：1592-1601.
［3］Samocha-Bonet D，Wong O，Synnott E-L，et al.Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients［J］.J Nutr，2011，141(7)：1233-1238.
［4］Nauck MA，Heimesaat MM，Orskov C，et al.Preserved incretin activity of glucagon-like peptide 1
［7-36 amide］ but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.［J］.J Clin Invest，1993，91(1)：301.
［5］Hayden MR，Patel K，Habibi J，et al.Attenuation of endocrine-exocrine pancreatic communication in type 2 diabetes：pancreatic extracellular matrix ultrastructural abnormalities［J］.J Cardiometab Syndr，2008，3(4)：234-243.
［6］World Health Organization：Definition，diagnosis and classification of diabetes mellitus and its complications：Report of a WHO Consultation.Part 1.Diagnosis and classification of diabetes mellitus［S］.Geneva，World Health Organization，1999.
［7］Delzenne N，Blundell J，Brouns F，et al.Gastrointestinal targets of appetite regulation in humans［J］.Obes.Rev.Off.J.Int.Assoc.Study Obes，2010，11(3)：234-250.
［8］Herrmann C，Gke R，Richter G，et al.Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients［J］.Digestion，1995，56(2)：117-126.
［9］Greenfield JR，Farooqi IS，Keogh JM，et al.Oral glutamine increases circulating glucagon-like peptide 1，glucagon，and insulin concentrations in lean，obese，and type 2 diabetic subjects［J］.Am J Clin Nutr，2009，89(1)：106-113.
［10］钟 雷，李 娟.谷氨酰胺在老年危重病患者中的应用价值［J］.华南国防医学杂志，2014，28(3)：209-211.
［11］Oliveira GP，Dias CM，Pelosi P，et al.Understanding the mechanisms of glutamine action in critically ill patients［J］.An Acad Bras Ciênc，2010，82(2)：417-430.
［12］Roth E.Nonnutritive effects of glutamine［J］.J Nut，2008，138(10)：2025S-2031S.
［13］Grau T，Bonet A，Miambres E，et al.The effect of L-alanyl-L-glutamine dipeptide supplemented total parenteral nutrition on infectious morbidity and insulin sensitivity in critically ill patients［J］.Crit Care Med，2011，39(6)：1263-1268.
［14］Opara EC，Petro A，Tevrizian A，et al.L-glutamine supplementation of a high fat diet reduces body weight and attenuates hyperglycemia and hyperinsulinemia in C57BL/6J mice［J］.J Nutr，1996，126(1)：273-279.
［15］Chia CW，Carlson OD，Kim W，et al.Exogenous glucose-dependent insulinotropic polypeptide worsens postprandial hyperglycemia in type 2 diabetes［J］.Diabetes，2009，58(6)：1342-1349.
［16］Chang J，Wu T，Greenfield JR，et al.Effects of intraduodenal glutamine on incretin hormone and insulin release，the glycemic response to an intraduodenal glucose infusion，and antropyloroduodenal motility in health and type 2 diabetes［J］.Diabetes Care，2013，36(8)：2262-2265.
［17］Van Wijk JPH，De Koning EJP，Castro Cabezas M，et al.Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes［J］.Diabetes Care，2005，28(4)：844-849.
［18］Xiao C，Dash S，Morgantini C，et al.Sitagliptin，a dipeptidyl peptidase-4 inhibitor，acutely inhibits intestinal lipoprotein particle secretion in healthy humans［J］.Diabetes，2014，63(7)：2394-2401.
［19］Dimitriadis G，Boutati E，Lambadiari V，et al.Restoration of early insulin secretion after a meal in type 2 diabetes：effects on lipid and glucose metabolism［J］.Eur J Clin Invest，2004，34(7)：490-497.
［20］Wasada T，Katsumori K，Saeki A，et al.Hyperuricemia and insulin resistance［J］.Nihon Rinsho Jpn J Clin Med，1996，54(12)：3293-3296.
［21］梁菁菁，蒋 戚，邹大进.羟氯喹治疗2型糖尿病［J］.东南国防医药，2012，14(3)：267-267.
［22］杨燕玲，吕飞娟.电话随访对提高2型糖尿病胰岛素治疗依从性的影响［J］.东南国防医药，2011，13(1)：63-63.

相似文献/References:

[1]潘全民.老年2型糖尿病患者步行前后血糖变化分析[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):525.[doi:10.3969/j.issn.1672-271X.2013.05.039]
[2]杜振双,张诚华.BillrothⅡ式胃切除术对患者血糖的影响[J].医学研究与战创伤救治(原医学研究生学报),2013,15(01):62.
[3]王佳薇,李 冰,郑玲玉.2型糖尿病158例临床路径护理分析[J].医学研究与战创伤救治(原医学研究生学报),2012,14(02):168.
[4]王加林,王 猛,杨文娟,等.131I治疗甲状腺功能亢进症合并2型糖尿病101例[J].医学研究与战创伤救治(原医学研究生学报),2011,13(02):109.
　WANG Jia-lin,WANG Meng,YANG Wen-juan,et al.Clinical study of 131I on the treatment of 101 cases of hyperthyroidism patients with type 2 diabetes mellitus[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(02):109.
[5]何述莉,董立新,施能彬,等.检测2型糖尿病患者尿微量白蛋白的临床意义[J].医学研究与战创伤救治(原医学研究生学报),2009,11(03):255.
[6]王 静,阮 芸,谭擎缨,等.α-酮酸在早期2型糖尿病肾病治疗中 的作用[J].医学研究与战创伤救治(原医学研究生学报),2008,10(06):426.
　WANG Jing,RUAN Yun,TAN Qing-ying,et al.The effect of α-keto acid on early diabetic nephropathy in type 2 diabetes mellitus[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2008,10(02):426.
[7]王 静,彭永平,宫剑滨,等.前列地尔对冠心病合并糖尿病患者介入治疗后造影剂肾病的影响[J].医学研究与战创伤救治(原医学研究生学报),2014,16(01):28.
　WANG Jing,PENG Yong-ping,GONG Jian-bin,et al.Effect of alprostadil on contrast-induced nephropathy in coronary heart disease patients with type 2 diabetes undergoing percutaneous coronary intervention[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(02):28.
[8]王爱民,徐向进,熊晓琴,等.2型糖尿病患者长期家庭血糖监测的随访分析[J].医学研究与战创伤救治(原医学研究生学报),2014,16(01):40.
　WANG Ai-min,XU Xiang-jin,XIONG Xiao-qin,et al.Following-up and nursing patients with type 2 diabetes mellitus by a long-term blood glucose monitoring at home[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(02):40.
[9]王静,谭擎缨,阮勇,等.2型糖尿病患者体脂含量及分布与血清内脂素水平的相关研究[J].医学研究与战创伤救治(原医学研究生学报),2014,16(05):465.[doi:10.3969/j.issn.1672-271X.2014.05.006]
　WANG Jing,TANG Qing-ying,RUAN Yong,et al.The relationship of visfatin with body fat content and fat distribution in type 2 diabetes[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(02):465.[doi:10.3969/j.issn.1672-271X.2014.05.006]
[10]熊晓琴,王爱民,罗晶,等.血糖负荷饮食疗法在非胰岛素治疗的2型糖尿病患者中的应用[J].医学研究与战创伤救治(原医学研究生学报),2014,16(05):469.[doi:10.3969/j.issn.1672-271X.2014.05.007]
　XIONG Xiao-qin,WANG Ai-min,LUO Jing,et al.The application of dietary glycemic load in non-insulin-treated type 2 diabetes[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(02):469.[doi:10.3969/j.issn.1672-271X.2014.05.007]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2015-03-20